Recent Finacing
Recent Raise
Adcentrx Therapeutics develops antibody‑drug conjugates using proprietary i‑Conjugation chemistry, advancing ADRX‑0706 (Nectin‑4‑targeting, DAR8 with AP052 tubulin payload) in Phase 1a/b from San Diego and Shanghai.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
